Biomea Fusion, Inc. (Nasdaq: BMEA) has announced the completion of enrollment in COVALENT‑211, a Phase II trial of its investigational oral therapy icovamenib for insulin‑deficient type 2 diabetes (T2D). The company also confirmed that enrollment in COVALENT‑212, which focuses on patients inadequately controlled despite GLP‑1 peptide therapy, is expected to finish by year‑end.
Icovamenib is a small molecule designed to down‑modulate menin, a transcriptional regulator implicated in beta‑cell biology. By targeting menin, Biomea aims to restore beta‑cell mass and function, potentially offering durable glycemic control after short treatment courses. Earlier data from the COVALENT‑111 trial showed HbA1c reductions of up to 1.5% in insulin‑deficient patients and 1.8% in GLP‑1 non‑responders, with improvements persisting nine months after treatment ended.
“Completing enrollment in COVALENT-211 is an important milestone for the icovamenib program as we continue to execute on our Phase II clinical trial development strategy,” said Mick Hitchcock, Ph.D., Interim Chief Executive Officer and Board Member of Biomea Fusion.
For peptide readers, the relevance lies in the GLP‑1 connection. GLP‑1 receptor agonists, peptide drugs that have transformed diabetes and obesity care, still leave 20–40% of patients uncontrolled. COVALENT‑212 directly addresses this gap, testing whether icovamenib can complement peptide therapies by improving outcomes in non‑responders.
The company expects topline 26‑week data from COVALENT‑211 in the first quarter of 2027, followed by COVALENT‑212 in the second quarter. Interim CEO Mick Hitchcock emphasized the milestone: “Our earlier clinical data demonstrated durable glycemic improvements and increased C‑peptide in insulin‑deficient patients following only 12 weeks of treatment, providing the foundation for COVALENT‑211 and our focus on this patient population.”
If successful, icovamenib could represent a new class of beta‑cell restorative therapy — one that works alongside peptide drugs rather than replacing them. For a field dominated by GLP‑1 peptides, this trial underscores how small molecules are being developed to extend peptide biology into new therapeutic strategies.